All News

Both doses of the GLP-1, GIP, glucagon triple agonist (9- and 12-mg) met all primary and key secondary endpoints and reduced CV risk factors as well, Eli Lilly said.

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

WHO experts weighed decades of high-quality studies against flawed analyses, finding consistent evidence that current vaccines pose no autism-related risk.

Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.

Your daily dose of the clinical news you may have missed.

Clevenger speaks to primary care clinicians, emphasizing 3 priorities: engage family as partners, ask about agitation, and recognize its danger to patient and caregiver.

Intranasal epinephrine emerges as a safe, effective alternative for anaphylaxis treatment, offering ease of use and promising real-world results.

Episode highlights include a new AD blood test for PCPs, sleep effects of elinzanetant among postmenopausal women, lung cancer screening gains, and more.

Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.

The inquiry follows internal requests for closer review of trial findings and real-world evidence; regulators have not yet indicated any planned actions.

The revised AHS guideline recommends treatments that offer the strongest benefit at ED discharge and identifies options with limited or no supporting evidence.

Your daily dose of the clinical news you may have missed.

A new rapid HIV test accurately differentiates vaccine-induced false positives from active HIV-1 infection, potentially improving diagnostics and vaccine trials.

Ob/gyn Dorr outlines how short clinical visits and symptom overlap cause many women to receive an antidepressant Rx instead of perimenopause care.

A new meta-analysis reveals monoclonal antibodies, including dupilumab, outperform placebo in treating moderate-to-severe atopic dermatitis.

Kallyope reported favorable phase 2b data in acute migraine for elismetrep, a novel ion channel protein, highlighting competitive efficacy and good tolerability.

Formulary restrictions and prior authorization requirements block access to newer PrEP options, while cost sharing over $50 cuts dispensing odds by 93%.

The 2026 annual updates to the Standards of Care in Diabetes include wider CGM use, guidance on dosing of antiobesity drugs, and glycemic management during cancer therapy.